255 related articles for article (PubMed ID: 16209554)
21. On the optimal design of the disassembly and recovery processes.
Xanthopoulos A; Iakovou E
Waste Manag; 2009 May; 29(5):1702-11. PubMed ID: 19138507
[TBL] [Abstract][Full Text] [Related]
22. Industry-Academic Collaboration in Oral Biopharmaceutics: The European IMI OrBiTo Project.
McAllister M; Zane P
Mol Pharm; 2017 Dec; 14(12):4129-4131. PubMed ID: 29198121
[No Abstract] [Full Text] [Related]
23. Multi criteria decision making to select the suitable method for the preparation of nanoparticles using an analytical hierarchy process.
Velmurugan R; Selvamuthukumar S; Manavalan R
Pharmazie; 2011 Nov; 66(11):836-42. PubMed ID: 22204128
[TBL] [Abstract][Full Text] [Related]
24. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry.
von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J
Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479
[TBL] [Abstract][Full Text] [Related]
25. Multiproduct Resin Reuse for Clinical and Commercial Manufacturing-Methodology and Acceptance Criteria.
Sharnez R; Doares S; Manning S; Mehta K; Mahajan E; To A; Daniels W; Glynn J; Dhamane S; Wen X; Wang Y; Gour P; Guenther C; Foley D; Hayes R; Mott A; Prabhu S; Tavalsky D; Hendershot M; Haas D; Hesslein A; Schuelke N; Tjandra H
PDA J Pharm Sci Technol; 2018; 72(6):584-598. PubMed ID: 30030349
[TBL] [Abstract][Full Text] [Related]
26. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
27. Trends in capacity utilization for therapeutic monoclonal antibody production.
Langer ES
MAbs; 2009; 1(2):151-6. PubMed ID: 20061821
[TBL] [Abstract][Full Text] [Related]
28. Process economics of industrial monoclonal antibody manufacture.
Farid SS
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):8-18. PubMed ID: 16899415
[TBL] [Abstract][Full Text] [Related]
29. Lexicographic ordering: intuitive multicriteria optimization for IMRT.
Jee KW; McShan DL; Fraass BA
Phys Med Biol; 2007 Apr; 52(7):1845-61. PubMed ID: 17374915
[TBL] [Abstract][Full Text] [Related]
30. Capacity optimization and scheduling of a multiproduct manufacturing facility for biotech products.
Shaik MA; Dhakre A; Rathore AS; Patil N
Biotechnol Prog; 2014; 30(5):1221-30. PubMed ID: 25079608
[TBL] [Abstract][Full Text] [Related]
31. Biopharmaceutical proteins: opportunities and challenges.
Birch JR; Onakunle Y
Methods Mol Biol; 2005; 308():1-16. PubMed ID: 16082021
[No Abstract] [Full Text] [Related]
32. Optimal load allocation of multiple fuel boilers.
Dunn AC; Du YY
ISA Trans; 2009 Apr; 48(2):190-5. PubMed ID: 19046585
[TBL] [Abstract][Full Text] [Related]
33. Application of agent-based system for bioprocess description and process improvement.
Gao Y; Kipling K; Glassey J; Willis M; Montague G; Zhou Y; Titchener-Hooker NJ
Biotechnol Prog; 2010; 26(3):706-16. PubMed ID: 20014420
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous beam geometry and intensity map optimization in intensity-modulated radiation therapy.
Lee EK; Fox T; Crocker I
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):301-20. PubMed ID: 16289912
[TBL] [Abstract][Full Text] [Related]
35. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots.
Sivakumar G
Biotechnol J; 2006 Dec; 1(12):1419-27. PubMed ID: 17136730
[TBL] [Abstract][Full Text] [Related]
36. [Scenario analysis--a method for long-term planning].
Stavem K
Tidsskr Nor Laegeforen; 2000 Jan; 120(1):100-1. PubMed ID: 10815501
[TBL] [Abstract][Full Text] [Related]
37. Decision support systems in water and wastewater treatment process selection and design: a review.
Hamouda MA; Anderson WB; Huck PM
Water Sci Technol; 2009; 60(7):1757-70. PubMed ID: 19809138
[TBL] [Abstract][Full Text] [Related]
38. An approach to process production reactive scheduling.
Hauptman B; Jovan V
ISA Trans; 2004 Apr; 43(2):305-18. PubMed ID: 15098589
[TBL] [Abstract][Full Text] [Related]
39. Flexibility--the guiding principle for antibody manufacturing.
Carson KL
Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
[TBL] [Abstract][Full Text] [Related]
40. MAGDM linear-programming models with distinct uncertain preference structures.
Xu ZS; Chen J
IEEE Trans Syst Man Cybern B Cybern; 2008 Oct; 38(5):1356-70. PubMed ID: 18784017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
